Effects of candesartan on left ventricular function, aldosterone and BNP in chronic heart failure

Aneta Aleksova; Serge Masson; Aldo P. Maggioni; Donata Lucci; Renato Urso; Lidia Staszewsky; Stefano Ciaffoni; Giuseppe Cacciatore; Gianfranco Misuraca; Michele Gulizia; Lucio Mos; Gianni Proietti; Calogero Minneci; Roberto Latini; Gianfranco Sinagra

doi:10.1007/s10557-012-6370-8

Effects of candesartan on left ventricular function, aldosterone and BNP in chronic heart failure

Aneta Aleksova, Serge Masson, Aldo P. Maggioni, Donata Lucci, Renato Urso, Lidia Staszewsky, Stefano Ciaffoni, Giuseppe Cacciatore, Gianfranco Misuraca, Michele Gulizia, Lucio Mos, Gianni Proietti, Calogero Minneci, Roberto Latini, Gianfranco Sinagra

Istituto di Ricerche Farmacologiche "Mario Negri"

Research output: Contribution to journal › Article

Abstract

Purpose Heart failure (HF) is characterized by activation of neurohormonal systems such as aldosterone and natriuretic peptides. In the absence of published data, CandHeart trial was designed to assess the effects on left ventricular (LV) function, aldosterone and brain natriuretic peptide (BNP) of candesartan in patients with HF and preserved (LVEF ≥ 40%) or depressed (LVEF

Original language	English
Pages (from-to)	131-143
Number of pages	13
Journal	Cardiovascular Drugs and Therapy
Volume	26
Issue number	2
DOIs	https://doi.org/10.1007/s10557-012-6370-8
Publication status	Published - Apr 2012

Keywords

Aldosterone
Candesartan
Heart failure
Left ventricular ejection fraction
Natriuretic peptide

ASJC Scopus subject areas

Pharmacology (medical)
Cardiology and Cardiovascular Medicine
Pharmacology

Access to Document

10.1007/s10557-012-6370-8

Fingerprint Dive into the research topics of 'Effects of candesartan on left ventricular function, aldosterone and BNP in chronic heart failure'. Together they form a unique fingerprint.

Cite this

Aleksova, A., Masson, S., Maggioni, A. P., Lucci, D., Urso, R., Staszewsky, L., Ciaffoni, S., Cacciatore, G., Misuraca, G., Gulizia, M., Mos, L., Proietti, G., Minneci, C., Latini, R., & Sinagra, G. (2012). Effects of candesartan on left ventricular function, aldosterone and BNP in chronic heart failure. Cardiovascular Drugs and Therapy, 26(2), 131-143. https://doi.org/10.1007/s10557-012-6370-8

Effects of candesartan on left ventricular function, aldosterone and BNP in chronic heart failure. / Aleksova, Aneta; Masson, Serge; Maggioni, Aldo P.; Lucci, Donata; Urso, Renato; Staszewsky, Lidia; Ciaffoni, Stefano; Cacciatore, Giuseppe; Misuraca, Gianfranco; Gulizia, Michele; Mos, Lucio; Proietti, Gianni; Minneci, Calogero; Latini, Roberto; Sinagra, Gianfranco.

In: Cardiovascular Drugs and Therapy, Vol. 26, No. 2, 04.2012, p. 131-143.

Research output: Contribution to journal › Article

Aleksova, A, Masson, S, Maggioni, AP, Lucci, D, Urso, R, Staszewsky, L, Ciaffoni, S, Cacciatore, G, Misuraca, G, Gulizia, M, Mos, L, Proietti, G, Minneci, C, Latini, R & Sinagra, G 2012, 'Effects of candesartan on left ventricular function, aldosterone and BNP in chronic heart failure', Cardiovascular Drugs and Therapy, vol. 26, no. 2, pp. 131-143. https://doi.org/10.1007/s10557-012-6370-8

Aleksova, Aneta ; Masson, Serge ; Maggioni, Aldo P. ; Lucci, Donata ; Urso, Renato ; Staszewsky, Lidia ; Ciaffoni, Stefano ; Cacciatore, Giuseppe ; Misuraca, Gianfranco ; Gulizia, Michele ; Mos, Lucio ; Proietti, Gianni ; Minneci, Calogero ; Latini, Roberto ; Sinagra, Gianfranco. / Effects of candesartan on left ventricular function, aldosterone and BNP in chronic heart failure. In: Cardiovascular Drugs and Therapy. 2012 ; Vol. 26, No. 2. pp. 131-143.

@article{431b7fdd87774ad1a731f9952597208e,

title = "Effects of candesartan on left ventricular function, aldosterone and BNP in chronic heart failure",

abstract = "Purpose Heart failure (HF) is characterized by activation of neurohormonal systems such as aldosterone and natriuretic peptides. In the absence of published data, CandHeart trial was designed to assess the effects on left ventricular (LV) function, aldosterone and brain natriuretic peptide (BNP) of candesartan in patients with HF and preserved (LVEF ≥ 40%) or depressed (LVEF ",

keywords = "Aldosterone, Candesartan, Heart failure, Left ventricular ejection fraction, Natriuretic peptide",

author = "Aneta Aleksova and Serge Masson and Maggioni, {Aldo P.} and Donata Lucci and Renato Urso and Lidia Staszewsky and Stefano Ciaffoni and Giuseppe Cacciatore and Gianfranco Misuraca and Michele Gulizia and Lucio Mos and Gianni Proietti and Calogero Minneci and Roberto Latini and Gianfranco Sinagra",

year = "2012",

month = apr,

doi = "10.1007/s10557-012-6370-8",

language = "English",

volume = "26",

pages = "131--143",

journal = "Cardiovascular Drugs and Therapy",

issn = "0920-3206",

publisher = "Kluwer Academic Publishers",

number = "2",

}

TY - JOUR

T1 - Effects of candesartan on left ventricular function, aldosterone and BNP in chronic heart failure

AU - Aleksova, Aneta

AU - Masson, Serge

AU - Maggioni, Aldo P.

AU - Lucci, Donata

AU - Urso, Renato

AU - Staszewsky, Lidia

AU - Ciaffoni, Stefano

AU - Cacciatore, Giuseppe

AU - Misuraca, Gianfranco

AU - Gulizia, Michele

AU - Mos, Lucio

AU - Proietti, Gianni

AU - Minneci, Calogero

AU - Latini, Roberto

AU - Sinagra, Gianfranco

PY - 2012/4

Y1 - 2012/4

N2 - Purpose Heart failure (HF) is characterized by activation of neurohormonal systems such as aldosterone and natriuretic peptides. In the absence of published data, CandHeart trial was designed to assess the effects on left ventricular (LV) function, aldosterone and brain natriuretic peptide (BNP) of candesartan in patients with HF and preserved (LVEF ≥ 40%) or depressed (LVEF

AB - Purpose Heart failure (HF) is characterized by activation of neurohormonal systems such as aldosterone and natriuretic peptides. In the absence of published data, CandHeart trial was designed to assess the effects on left ventricular (LV) function, aldosterone and brain natriuretic peptide (BNP) of candesartan in patients with HF and preserved (LVEF ≥ 40%) or depressed (LVEF

KW - Aldosterone

KW - Candesartan

KW - Heart failure

KW - Left ventricular ejection fraction

KW - Natriuretic peptide

UR - http://www.scopus.com/inward/record.url?scp=84862756380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862756380&partnerID=8YFLogxK

U2 - 10.1007/s10557-012-6370-8

DO - 10.1007/s10557-012-6370-8

M3 - Article

AN - SCOPUS:84862756380

VL - 26

SP - 131

EP - 143

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 2

ER -